MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy.

The company was founded in 2012 and is headquartered in Brisbane, California.

MyoKardia headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $9.8B in funding across 100 round(s). With a team of 251-500 employees, MyoKardia is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - MyoKardia, raised $38.0M. Discover more about their projects, partnerships, and impact on our platform.